Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04196530 · ClinicalTrials.gov registry record · Phase 1
BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab
A Phase 1 study of Tumor, Solid, sponsored by Eikon Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 5
- Study locations
NCT04196530: Completed Phase 1 study of Tumor, Solid, sponsored by Eikon Therapeutics.
NCT04196530 is a Phase 1 study of Tumor, Solid that has completed, run by Eikon Therapeutics. The registered enrollment target is 40 participants, below the 240-participant average among 11 other Tumor, Solid trials with a reported enrollment target (83% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04196530, a Phase 1 study of Tumor, Solid, has completed, sponsored by Eikon Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 5
- Study locations
Study Summary
A Phase 1 Open-label Dose Escalation Study of BDB001 in Combination with Atezolizumab in Subjects with Advanced Solid Tumors
Primary Outcome
Safety and tolerability of BDB001 in combination with atezolizumab as measured by the incidence of adverse events and any dose limiting toxicities (DLT)
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG BDB001 (EIK1001)
Study Locations (5)
Texas
- NEXT Oncology - San Antonio
- South Texas Accelerated Research Therapeutics (START) - San Antonio
California
- Angeles Clinic - Los Angeles
Florida
- Florida Cancer Specialists - Sarasota
Tennessee
- Tennessee Oncology - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2019-11-21 |
| Est. Completion | 2024-08-15 |
| Phase | Phase 1 |
What the finished NCT04196530 record still lists
NCT04196530 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 240-participant average among 11 other Tumor, Solid trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Tumor, Solid appearing as the primary indexed condition, and to 2 interventions - of which Atezolizumab is the first listed.
NCT04196530 lists 5 locations in 4 states (Texas, California, Florida).
Frequently Asked Questions
What is clinical trial NCT04196530 about?
NCT04196530 is a clinical study titled "BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab". A Phase 1 Open-label Dose Escalation Study of BDB001 in Combination with Atezolizumab in Subjects with Advanced Solid Tumors
What is the current status of trial NCT04196530?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2019-11-21. Estimated completion is 2024-08-15.
What conditions does trial NCT04196530 study?
This clinical trial studies the following conditions: Tumor, Solid.
What interventions are being tested in trial NCT04196530?
The interventions under investigation include: Atezolizumab (DRUG), BDB001 (EIK1001) (DRUG).
Who is sponsoring clinical trial NCT04196530?
This trial is sponsored by Eikon Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04196530 being conducted?
This trial has 5 study locations across California, Florida, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tumor, Solid
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04196530's enrollment target sits among peer trials
40 9th of 11 higher than 3 of 11 other Tumor, Solid trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tumor, Solid trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
TumorGlow Intraoperative Molecular Imaging (IMI)
RECRUITING · Phase 1
-
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
RECRUITING · Phase 1
-
Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment
RECRUITING · Phase 1
-
An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI